UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27

Benzinga Newsdesk www.benzinga.com Neutral 69.1%

Neg 0% Neu 69.1% Pos 0%

UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.